Skip to main content
ADTX
NASDAQ Life Sciences

Aditxt Faces New Nasdaq Delisting Threat Over Negative Equity, Compounding Prior Bid Price Issue

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$0.142
Mkt Cap
$95.626K
52W Low
$0.106
52W High
$53,450.606
Market data snapshot near publication time

Summary

Aditxt, Inc. received an additional Nasdaq delisting notice due to its negative stockholders' equity, further jeopardizing its listing status ahead of a scheduled hearing for a prior minimum bid price deficiency.


Key Events

  • New Delisting Notice Received

    Aditxt received a letter from Nasdaq on May 27, 2026, notifying the company of non-compliance with the minimum stockholders' equity requirement of $2.5 million.

  • Significant Financial Deficiency

    The company reported stockholders' equity of negative $35.17 million as of March 31, 2026, far below the Nasdaq requirement. It also fails alternative listing standards for market value of listed securities and net income.

  • Aggravated Delisting Risk

    This new deficiency serves as an additional basis for delisting and will be considered by the Nasdaq Hearings Panel at the previously scheduled hearing on June 11, 2026, which was set to address the prior minimum bid price non-compliance.

  • Potential Third Deficiency Identified

    The company has also determined it is not in compliance with the $1 million Market Value of Publicly Held Shares requirement, which may also be considered by the Panel.


Analysis

This filing reveals a new and significant reason for Aditxt's potential delisting from Nasdaq: a severe deficiency in stockholders' equity, which stands at a negative $35.17 million against a $2.5 million requirement. This adds to an existing delisting notice for failing the minimum bid price requirement and a potential third deficiency for Market Value of Publicly Held Shares. The accumulation of these issues significantly increases the likelihood of delisting, which would severely impair the company's ability to raise capital and maintain liquidity, raising substantial doubt about its ability to continue as a going concern.

At the time of this filing, ADTX was trading at $0.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $95.6K. The 52-week trading range was $0.11 to $53,450.61. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADTX - Latest Insights

ADTX
May 29, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
May 22, 2026, 5:03 PM EDT
Filing Type: PRE 14A
Importance Score:
9
ADTX
May 20, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
9
ADTX
May 15, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
May 14, 2026, 8:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ADTX
May 08, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
9
ADTX
May 08, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
9
ADTX
May 01, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
ADTX
Apr 23, 2026, 4:30 PM EDT
Filing Type: 424B3
Importance Score:
8
ADTX
Apr 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9